Comparative Pharmacology
Head-to-head clinical analysis: IMDUR versus NITRO IV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMDUR versus NITRO IV.
IMDUR vs NITRO IV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isosorbide mononitrate is a nitrate vasodilator that relaxes vascular smooth muscle via conversion to nitric oxide (NO), which activates guanylate cyclase, increasing cGMP levels, leading to vasodilation. It primarily dilates veins (venodilation) with lesser effects on arteries, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Nitroglycerin is a vasodilator that primarily acts by relaxing vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase to increase cGMP, leading to venodilation and, at higher doses, arterial dilation. This reduces preload and afterload, decreasing myocardial oxygen demand.
Initial: 30-60 mg orally once daily; titrate to 120 mg once daily as tolerated. Maximum: 240 mg once daily.
Initial infusion rate 5 mcg/min via continuous IV infusion, titrate by 5 mcg/min every 3-5 minutes until response; usual maintenance dose 10-20 mcg/min; maximum 200 mcg/min.
None Documented
None Documented
Terminal elimination half-life of isosorbide mononitrate is approximately 5 hours. This supports once-daily dosing for IMDUR (extended-release formulation) due to prolonged absorption phase.
1-4 minutes (rapidly cleared from blood); terminal half-life ~2-3 minutes due to rapid biotransformation in RBCs and vascular tissue.
Isosorbide dinitrate (IMDUR active metabolite? Actually IMDUR is isosorbide mononitrate, the active metabolite of isosorbide dinitrate. For isosorbide mononitrate: renal excretion is approximately 96% as metabolites, with about 2% unchanged; biliary/fecal excretion is minimal, <2%.
Renal (minimal, <1% unchanged) and hepatic metabolism; metabolites excreted renally.
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator